BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™in patients with pulmonary arterial hypertension.

Saved in:
Bibliographic Details
Title: BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™in patients with pulmonary arterial hypertension.
Authors: Spikes, Leslie A.1 LSpikes@kumc.edu, Bajwa, Abubakr A.2, Burger, Charles D.3, Desai, Sapna V.4, Eggert, Michael S.5, El‐Kersh, Karim A.6, Fisher, Micah R.7, Johri, Shilpa8, Joly, Joanna M.9, Mehta, Jinesh10, Palevsky, Harold I.11, Ramani, Gautam V.12, Restrepo‐Jaramillo, Ricardo13, Sahay, Sandeep14, Shah, Trushil G.15, Chunqin Deng16, Miceli, Melissa17, Smith, Peter16, Shapiro, Shelley M.18
Source: Pulmonary Circulation. Apr2022, Vol. 12 Issue 2, p1-14. 14p.
Database: Academic Search Ultimate
Description
ISSN:20458932
DOI:10.1002/pul2.12063